Thermo Fisher Scientific has announced the completion of its tender offer for Dionex Corporation.
Thermo Fisher Scientific has announced the completion of its tender offer for Dionex Corporation.
"The acquisition of Dionex is consistent with our strategy of accelerating growth by increasing our depth of capabilities in innovative technologies and emerging markets," said Marc N. Casper, president and chief executive officer of Thermo Fisher. "This combination creates a leading offering for our customers in chromatography instruments, software, consumables and services. With Dionex, we will expand our presence in attractive applied markets, including environmental analysis, water testing and food safety, and increase our commercial capabilities in China and other growing Asia-Pacific regions. We welcome Dionex employees to the Thermo Fisher team and look forward to working together to fulfill our mission, which is to enable our customers to make the world healthier, cleaner and safer."
In a letter to Dionex customers, Kevin Chance, president of the Scientific Instruments division of Thermo Fisher, said “This acquisition represents a significant step forward in our ability to serve science, and enables us to offer the industry’s most extensive portfolio of products and services, offering greater value to an even wider range of applications.”
He reassured customers that “While we aim to bring positive new products and service to our customers over time, we also want to preserve what is valued now. Manufacturing and support will remain at existing facilities worldwide, and your primary contacts at Dionex will continue to be your primary contacts now that Dionex is part of Thermo Fisher Scientific.”
Reports indicate that approximately 93% of Dionex's issued and outstanding shares have been validly tendered. The remaining shares are expected to be acquired through a short-form merger.
For more information visit www.thermofisher.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.